Psyence BioMed Ltd. (NASDAQ: PBM) announced that members of its executive leadership team will travel to the United States in the coming weeks to meet with researchers, institutions, industry leaders, and government stakeholders involved in psychedelic medicine research and policy initiatives.

The company said the visit follows recent U.S. policy developments supporting increased research collaboration and clinical investigation involving psychedelic compounds, including ibogaine. Chief Executive Officer Jody Aufrichtig submitted a formal letter to President Donald J. Trump and U.S. Secretary of Health and Human Services Robert F. Kennedy Jr. regarding the Administration's research initiatives involving psychedelic compounds.

The purpose of the engagement initiative is to educate stakeholders on the complexity, regulatory considerations, and scientific infrastructure required to manufacture pharmaceutical-grade ibogaine under Good Manufacturing Practice standards for regulated clinical research, according to the press release.

Psyence BioMed operates ibogaine manufacturing capabilities in Africa through its strategic investment in PsyLabs. PsyLabs operates a GMP-compliant facility in Southern Africa focused on the cultivation, extraction, purification, and manufacturing of psychedelic compounds from natural sources.

"We believe global interest in ibogaine research continues to accelerate, particularly as policymakers, researchers, and healthcare institutions explore innovative approaches to serious mental health conditions," Aufrichtig said. "Our objective during this visit is to contribute constructively to those conversations by sharing our expertise and helping stakeholders better understand the highly specialized process required to produce compliant pharmaceutical-grade ibogaine suitable for regulated research environments."

The company noted it has experienced increased engagement from U.S.-based researchers and institutions seeking information regarding compliant ibogaine manufacturing capabilities and supply availability for future regulated research initiatives following recent U.S. policy announcements.

Psyence BioMed is a biopharmaceutical company focused on developing nature-derived psychedelic compounds for clinical research and therapeutic applications.